Vientiane, Laos - June 9, 2026 -Lucius Pharmaceutical is focused on providing effective, safe, and reliable medications and services for patients all over the world., today announced LuciMird (Mirdametinib) have been approved by the Ministry of Health of Laos. Mirdametinib is a medication used for the treatment of people with…
Vientiane, Laos - December 30, 2025 -Lucius Pharmaceutical is focused on providing effective, safe, and reliable medications and services for patients all over the world., today announced LuciAcor (Acoramidis) have been approved by the Ministry of Health of Laos. Approved drugs are: Acoramidis : sold under the brand name LuciAcor .…
Vientiane, Laos - November 11, 2025 -Lucius Pharmaceutical is focused on providing effective, safe, and reliable medications and services for patients all over the world., today announced LuciRevu (Revumenib) have been approved by the Ministry of Health of Laos. Approved drugs are: Revumenib : sold under the brand name LuciRevu. Revumenib…
Vientiane, Laos - October 6, 2025 -Lucius Pharmaceutical is focused on providing effective, safe, and reliable medications and services for patients all over the world., today announced LuciNiro (Nirogacestat) have been approved by the Ministry of Health of Laos. Approved drugs are: Nirogacestat : sold under the brand name LuciNiro. Nirogacestat…
![BIGBEAR Pharmaceutical объявляет об одобрении биниметиниба[Binimetinib] и энкорафениба[Encorafenib] в Лаосе](https://lienteh.net/wp-content/uploads/2024/10/2024-10-1274-280x280.webp)
Вьентьян, Лаос - 12 октября 2024 г. - BigBear Pharma, ведущая биофармацевтическая компания, занимающаяся разработкой и коммерциализацией инновационных методов лечения рака, сегодня объявила, что Биниметиниб [Binimetinib] и Энкорафениб [Encorafenib] были одобрены Министерством здравоохранения Лаоса. Одобренные препараты: Биниметиниб [Binimetinib] продается под торговой маркой MEKTODX, регистрационный номер в Лаосе: 09L1096/24 Энкорафениб [Encorafenib]…
Vientiane, Laos - October 12 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Binimetinib and Encorafenib have been approved by the Ministry of Health of Laos. Approved drugs are: Binimetinib sold under the brand name MEKTODX, Laos registration number: 09L1096/24 Encorafenib…
Vientiane, Laos - September 20, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that 2 products have been approved by the Ministry of Health of Laos. Approved drugs are: Letermovir: sold under the brand name LETEDX.Letermovir is an antiviral drug…
Vientiane, Laos - July 14, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Adagrasibm have been approved by the Ministry of Health of Laos. Approved drugs are: Adagrasib: sold under the brand name ADADX. Adagrasib, a KRAS G12C inhibitor, irreversibly and selectively binds KRAS G12C,…
Vientiane, Laos - May 30, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Larotrectinib have been approved by the Ministry of Health of Laos. Approved drugs are: Larotrectinib sold under the brand name LARODX. Larotrectinib is an inhibitor of tropomyosin kinase…
June 24, 2024, Haihe Biopharma Co., Ltd. (referred as “Haihe”) announced that Ministry of Health, Labor and Welfare of Japan (厚生労働省) approved New Drug Application (“NDA”) of Gumarontinib (SCC244) for the treatment of unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping mutation. The indication…
Вьентьян, Лаос – 8 апреля 2024 г. – BigBear Pharma, ведущая биофармацевтическая компания, занимающаяся разработкой и коммерциализацией инновационных методов лечения рака, сегодня объявила, что два продукта были одобрены Министерством здравоохранения Лаоса. Разрешенные препараты: Селуметиниб (Selumetinib): продается под торговой маркой SEMEDX. Селуметиниб (Selumetinib) был одобрен для продажи в США 10 апреля…
Vientiane, Laos - April 8, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that 2 products have been approved by the Ministry of Health of Laos. Approved drugs are: Selumetinib: sold under the brand name SEMEDX. Selumetinib was approved for…
Original Brand drug Epclusa （Sofosbuvir/Velpatasvir） is the world’s first all-oral, pan-genotypic, single-tablet hepatitis C treatment regimen, taken orally once daily, for all 6 genotypes (GT-1, -2, -3, -4, -5,-6) Treatment of hepatitis C patients. Currently, there are 26 versions of sofosbuvir/velpatasvir tablets available in the Asia-Pacific region. Generic Drugs Sofosbuvir-velpatasvir Other…
September 16, 2023 (Vientiane) Laos BIGBEAR Pharmaceuticals announced has recently made a significant stride in the field of immune inflammatory disease treatment with the approval of four breakthrough Janus kinase (JAK) inhibitors. The Lao Health Authority has given the green light to TOFADX, RUSODX, UPADX, and DUVACIDX, marking a new…
The Food and Drug Department of the Ministry of Health in Lao PDR is responsible for regulating the registration of pharmaceutical products in the country . They provide a range of forms and guidelines on their website to assist with the registration process . For instance, you can download the…
MISSISSAUGA, ON, Oct. 29, 2021 Libtayo® (cemiplimab) is now approved in Canada for the treatment of adults with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).The approval of Libtayo follows the European Commission (EC) approval announced in June 2021 and the US in February 2021. With today's announcement, Libtayo is now offered as…
LUCIUS Pharmaceutical announces the approval LuciMird in Lao…
LUCIUS Pharmaceutical anuncia la aprobación de LuciAcor en L…Компания LUCIUS Pharmaceutical объявляет об одобрении препар…
LienTeh Network Announces New Content Strategy Focused on Lo…
LienTeh Network anuncia una nueva estrategia de contenido ce…
Copyright © 2021-2022 LienTeh.net All rights reserved.
